Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | VEGFA | P15692 | 3/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16785303 | 0.83 | PPARD (0.41) | PPARGEPAS1PPARDTTR | |
| SCHEMBL14663509 | 0.83 | PPARD (0.41) | EPAS1PPARDTTR | |
| SCHEMBL875925 | 0.82 | PPARD (0.44) | PPARDTTR | |
| SCHEMBL15900735 | 0.81 | PPARG (0.43) | PPARG | |
| SCHEMBL14661984 | 0.81 | TLR8 (0.40) | EPAS1PPARDTTR | |
| SCHEMBL876950 | 0.80 | EPAS1 (0.44) | VEGFAEPAS1PPARD | |
| SCHEMBL875726 | 0.80 | CYP3A4 (0.51) | PPARGVEGFAEPAS1TTR | |
| SCHEMBL14656192 | 0.80 | TTR (0.49) | PPARGPPARDTTR | |
| SCHEMBL2032911 | 0.78 | PPARG (0.51) | PPARGVEGFAEPAS1 | |
| SCHEMBL14656314 | 0.78 | HTR2A (0.49) | EPAS1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948452-B1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-9708330-B2 | 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-20150361082-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| EP-2948452-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-9051325-B2 | Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| WO-2014114694-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
| US-20140213599-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
| WO-2014114694-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213599-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | PPARG 576/4885VEGFA 2970/4885EPAS1 394/4885 |
| US-20150361082-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | PLA2G4A, PLA2G4C, PLA2G4B | PPARG 796/4885VEGFA 4039/4885EPAS1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.